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Abstract
Objective The aim of this study was to evaluate the impact of patent expiry on drug prices by means of a systematic litera-
ture review.
Methods A systematic literature search was performed in PubMed to identify all published literature on the impact of patent 
expiration on drug prices. Additional literature was identified using a less distinct syntax in Google Scholar and EconLit. 
Data extraction followed a standardized assessment form containing the domains study type, study aim, reported outcomes, 
number of drugs and drug classes assessed, and originators or generics assessed.
Results The 16 identified studies that assessed impact of patent expiry on drug prices showed that price developments after 
patent expiration varied between countries. The included studies assessed price developments for the USA, Canada, Australia, 
the UK, the Netherlands, Germany and France, Spain, Italy, Norway, Sweden and Denmark. The number of drugs included 
within different studies ranged between 1 and 219. The identified studies indicated that drug prices decreased significantly 
after patent expiry with drug price ratios ranging from 6.6 to 66% 1–5 years after patent expiry.
Conclusion Drug prices decrease significantly after patent expiry. The extent of this price reduction varied greatly between 
products and countries. For this reason, country-specific analyses on price developments after patent expiry should be used 
when these are considered in decision making. Future research should be dedicated to gathering more country-specific data 
to reduce the uncertainty with regard to price developments.
Key Points for Decision Makers 
Drug prices decrease significantly after patent expiry.
Country-specific data on drug price developments is 
lacking for the European market.
Country-specific data on drug price developments should 
be used in decision making where drug prices play a 
prominent role.
1 Introduction
In high-income countries, total health expenditure rep-
resented 12.3% of the gross domestic product (GDP) in 
2014 [1]. Following the great recession of 2008, health 
expenditures have once again become a major target of 
cost-containment efforts at national level [2]. In the Neth-
erlands, the total healthcare expenditure rose from €67 
billion in 2005 to €96 billion in 2016. The budget spend 
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on pharmaceuticals during the same time period remained 
rather stable though, and accounted for approximately 10% 
of these healthcare expenditures [3]. Though newly intro-
duced pharmaceuticals may pressure a given healthcare 
budget, patent expiration and associated price decreases 
may offset this burden. After a patent expiry or loss of 
other exclusivity rights, generic copies of the originator 
can be produced and marketed without a license from the 
originator company [4]. The market entry of generic cop-
ies of originator drugs after patent expiry and subsequent 
generic substitution play a role in the cost containment in 
health care and pharmaceuticals [5].
Patents can foster innovation as they provide the manu-
facturer the opportunity for a temporary monopoly and 
a period of market exclusivity [6]. During the period of 
market exclusivity pharmaceutical companies can recoup 
the opportunity costs made during the drug development 
process. The right of market exclusivity for new products 
stimulates new investments in Research and Development 
(R&D). Several factors may influence the duration of mar-
ket exclusivity, including: the moment of patent filing, the 
duration of the R&D process afterwards, the registration 
process and time to approval/reimbursement by the US 
Food and Drug Administration (FDA)/European Medicine 
Agency (EMA) and national health technology assess-
ment (HTA) agencies, and the duration before approval 
of generic drugs [7].
The aim of this study was to evaluate available quantita-
tive data regarding impact of patent expiry on drug prices 
by means of a systematic literature review.
2  Methods
2.1  Literature Search
A systematic literature search was performed on peer-
reviewed literature in the PubMed, EconLit and Google 
Scholar databases in February 2018. A comprehensive 
search syntax that included the terms “patent”, “brand”, 
“licensed”, “market exclusivity”, “drug”, “medicine”, 
“pharmaceutical”, “expiration”, “expiry”, “generic entry”, 
“generic substitution”, “lifecycle”, “originator”, “price”, 
“cost”, “cost effectiveness”, “ICER” was run through the 
PubMed Database (Appendix 1). A subsequent literature 
search was performed using a less distinct syntax with the 
terms “generic substitution” and “patent expiry” for titles 
and abstracts in the EconLit database and Google Scholar. 
Additionally, the references in the bibliography of the papers 
selected from the included databases were reviewed manu-
ally. Searches were limited to publications from the year 
2000 onwards.
2.2  Literature Selection
The selected literature was limited to full publications of 
original research. Studies were included if they reported 
quantitative outcomes on the impact of patent expiration 
on drug prices. Exclusion criteria included: (a) papers 
were not written in English or Dutch, or (b) the endpoints 
(reported outcomes) on price developments did not include 
or were not comparable to moment of initial generic entry. 
Reported endpoints on price developments after patent 
expiry were extracted as outcome for this study. The selec-
tion of literature and data extraction was performed by two 
authors (GTV and QC). In case of disagreement, a third 
author was consulted(MHR).
2.3  Data Analysis
A standardized assessment form was developed to extract 
data, which included the following domains: study type, 
study aim, reported outcomes and results, number of drugs 
assessed, drug class, originators or generics assessed, and 
time point after patent expiry of reported price develop-
ment outcomes. The moment of patent expiry was defined 
as the moment of initial generics entry. A generic drug 
was defined as a pharmaceutical drug that is equivalent 
to a brand-name product in route of administration, qual-
ity, performance, and intended use. Reported outcomes 
on price developments were translated into price ratios 
compared to the price of the original product at moment 
of patent expiry, where necessary.
3  Results
3.1  Results of Data Extraction
The systematic PubMed search yielded 262 unique cita-
tions. After screening for titles and abstracts 214 cita-
tions were excluded based on the exclusion criteria. The 
remaining 48 articles underwent full-text examination for 
eligibility, which resulted in the inclusion of ten articles 
[8–17]. The remaining 38 articles were excluded as they 
examined policy changes, prescription patterns, or total 
healthcare expenditures rather than price developments 
after patent expiry. The literature search in the EconLit 
database yielded 36 articles of which 11 were deemed 
eligible for full-text examination. Seven articles met the 
inclusion criteria of which two were duplicates from the 
PubMed search [18–24]. One additional study that met the 
selection criteria was identified in the literature search in 
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Google Scholar [6]. As a result, in total 16 studies were 
selected for data extraction (Fig. 1).
Table 1 summarizes the included studies in this review. 
Studies focused on 12 different countries over three conti-
nents. The majority of the studies focused on or included the 
USA (n = 9) [6, 8, 10, 11, 15–18, 21, 22, 24]. Furthermore, 
one study focused on Canada [14], one study on the Nether-
lands [12], one on Spain [20], and four studies assessed the 
price developments in multiple countries [9, 13, 19, 23]. In 
total 16 studies examined the impact of patent expiration on 
drug list prices over time [6, 8–15, 18–24].
3.2  Time Period and Number of Drugs Included
Eleven studies identified and assessed all drugs facing initial 
generic entry within their study period, to provide a repre-
sentative overview of the impact of patent expiry on price 
for the total market [6, 8, 10, 11, 13–15, 18, 20, 21, 24] (see 
also Tables 1 and 2). The remaining five articles focused 
on a specific therapeutic area or specific drugs [19, 22, 23].
All studies included in this review assessed price develop-
ments of between one and 129 different drugs. Price devel-
opments of the included drugs were assessed between 1984 
and 2009, and the average study period length was 7.5 years 
[8].
3.3  Definition of Patent Expiry
As the moment of patent expiration varies between coun-
tries, and drugs are often protected by several different pat-
ents, it can be challenging to define a set point for patent 
expiry. Notably, studies included in this review that assessed 
the impact of expiry on drug prices used varying defini-
tions for the set time of patent expiry. Seven studies used 
the time of initial generic entry as a surrogate endpoint for 
the moment of patent expiry [8, 10, 11, 14, 20, 22], whereas 
in six the date of patent expiry was available within the 
Fig. 1  Flow diagram of the study selection process
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used database (MIDAS-IMS International database and the 
IMS Generic Spectra database) [6, 13, 19, 21, 23, 24]. The 
remaining three studies that assessed the impact of expiry 
dates on drug prices did not specify how the patent expiry 
date was set [9, 12, 15].
3.4  Outcome Measurement and Data Use
Various outcome measures were used in the studies included 
in this review. Whereas seven studies assessed the impact of 
generic entry on both originator and generic prices [6, 15, 
18, 19, 21, 22, 24], five studies only reported generic price 
developments [8–10, 12, 20], and four studies focused only 
on price developments of originator drugs after generic entry 
[11, 13, 14, 23].
Furthermore, 12 studies defined their outcome as a price 
ratio compared to the originator price at the moment before 
patent expiry (seven for both generic and originator drugs, 
three for generics only and three for originators only) [6, 8, 
10, 13–15, 18, 20–24], one study reported the outcome as 
wholesale price per tablet [9], and two studies used price 
per Defined Daily Dose (DDD) as the comparative outcome 
measurement [12, 18]. In addition, two studies reported on 
the price rigidity of originator drugs and reported price 
changes in percentages at certain time points after patent 
expiry [11, 23].
The type of data used to estimate the impact of patent 
expiry on drug prices also varied between studies. Thirteen 
studies used drug-utilization data, which allowed for the cor-
rection of the proportionate use of different strengths and 
administration forms of both originators and generics [6, 
8–10, 12, 13, 15, 18, 19, 21–24], whereas three other stud-
ies only used price data [11, 14, 20]. A further three studies 
used the assumed average maintenance dose per day for a 
Table 1  Overview of studies included in the review
ACE angiotensin converting enzyme, PPI proton pump inhibitor, EP Market Exclusivity Period, USA United States, NL Netherlands, UK United 
Kingdom, GER Germany, FR France
a The same active ingredient in different countries was counted separately (four countries total considered in the paper
b Different administration forms of the same drugs counted as separate products
Study, publication year 
and reference
Country Included generic or 
originators
Number of drugs 
assessed
Therapeutic category Study period
Kelton et al. (2014) [8] USA Generic 83 Various 1991–2008
Clarke et al. (2010) [9] Australia and UK Generic 1 Simvastatin 2002–2009
Berndt et al. (2007) [10] USA Generic 11 Various 1999–2003
Hong et al. (2005) [11] USA Originator 27 Various (oral and non-
antibiotic)
1987–1992
Boersma et al. (2005) 
[12]
NL Generic 3 H2 receptor antagonists 1996–1999
Magazzini et al. (2004) 
[13]
USA, UK, GER, FR Originator 269a Various 1987–1996
Lexchin et al. (2004) [14] Canada Originator 81 drugs in 144 
 presentationsb
Various 1990–1998
Suh et al. (2000) [15] USA Generic and Originator 35 Various 1984–1987
Lakdawalla et al. (2006) 
[6]
USA Generic and Originator 101 Various 1992–2002
Berndt et al. (2011) [18] USA Generic and Originator 219 brands Various 1984–2009
Kanavos et al. (2008) 
[19]
UK, Canada, GER, 
FR, Spain, Italy, 
USA
Generic and Originator 12 molecules Various 2000–2005
Puig-Junoy Jaume et al. 
(2012) [20]
Spain Generic 8 Various Jan–Jul 2008
Saha et al. (2006) [21] USA Generic and Originator 40 Various 1991–1998
Wiggins et al. (2004) 
[22]
USA Generic and Originator 98 Anti-infectives 1984–1990
Vandoros et al. (2013) 
[23]
Germany, UK, NL, 
Sweden, Norway, 
Denmark
Originators 12 Plain ACE-inhibitors, 
atypical anti-psychot-





USA Generic and Originator 40 Various 1992–1998
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Table 2  An overview of the outcomes of price developments after patent expiration
USA United States, NL Netherlands, UK United Kingdom, GER Germany, FR France
a Considered the same active ingredient in different countries as different (four countries total)
b Outcomes are estimations from a graph
Study Region Number of drugs Price ratio after patent expiry Time point of measurement of price 
ratio (after generic entry)










Berndt [10] USA 1
10
37% (5− generic entries)
25% (5 + generic entries)
27% average with product line 
extensions




Lakdawalla [6] USA 101 58% (generic)
100% (originator)
18 months
Lexchin [14] USA, Canada 81 100% (originator) Not specified (before and at moment 
of initial generic entry and subse-
quent entry)
Hong [11] USA 27 100% (no change originator) (aver-
age)
5 years before and after entry




9 years after initial generic entry
Clarke [9] Australia UK 1 50% Australia (± 15% decrease in 
price per year)
4% UK (More than twice the rate, 
no exact number shown)
4 years
Kelton [8] USA 83 Between 11 and 41% (No overall 
average) extra firm leads to 13% 
price-drop on average.
21 quarters after generic entry
Berndt [18] USA 219 64.9% for all drugs across nine 
therapeutic areas
24 months after initial generic entry
Kanavos [19] UK, Canada, GER, FR, Spain, Italy, 
USA
12 Varies greatly between products and 
countries; minimum generic price 
47% lower in countries with refer-
ence pricing
Not specified
Puig-Junoy [20] Spain 8 Amlodipine 53%
Fluoxetine 21%
Not specified
Saha [21] USA 83 Ranged widely between drugs; 
68/83 where priced lower, 15 
where less then 50% of the origi-
nal price
1 year after initial generic entry
Wiggins [22] USA 98 Depending on the number of sellers; 
50% with 2/3 sellers, less then 
33% with 4 + sellers, and 6.6% 
with > 40 sellers
Not specified, analysis based on 
number of sellers
Vandoros [23] GER, UK, NL, SWE, Norway, 
Denmark
12 Overall originators 5% higher price 
in markets where a generic prod-
uct is present:







Time point not specified
Grabowski [24] USA 40 On average for all included drugs: 
55%
12 months after initial generic entry
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drug (DDDs) as a comparative measure [12, 13, 15], and 
three more used real-world prescription or utilization data 
for the investigated drugs to weight prices [6, 8, 22]. Lastly, 
the remaining two studies did not elaborate on how utiliza-
tion data was used to weight prices [9, 10].
3.5  Outcomes
The 12 studies that assessed generic prices after patent 
expiry showed price ratios ranging from 6.6% up to 66% 
after 1–5 years after initial generic entry (see Table 2) [6, 
8–10, 12, 15, 18–22, 24]. Both Berndt et al. [10] and Wig-
gins et al. [22] additionally detected an inverse relation 
between the number of generic entrants and the drug price, 
although beyond five generic entrants no further impact on 
the drug price was observed [10]. Similarly, Kelton et al. 
showed that for every additional generic introduced, the rela-
tive reimbursement price of a drug would decrease with 13% 
on average [8].
Of the six studies that assessed the impact of patent expi-
ration on originator prices [6, 11, 13–15, 23], the four stud-
ies that focused on the USA concluded that originator prices 
were rigid and overall did not alter significantly after patent 
expiry [6, 11, 14, 15]. However, both the studies by Maga-
zzini et al. and Vandoros et al. showed that the impact of 
patent expiration varied between different countries [13, 23]. 
For example, Magazzini found that in France the price after 
patent expiry was rigid for originators, while in Germany 
and the UK originator prices decreased by 25% on average 
in the 9 months after patent expiry, and in the USA origina-
tor prices increased by 10–20% over the same period [13]. 
Based on the analyses in Denmark, Germany, Norway, Swe-
den, the UK, and the Netherlands, Vandoros reported that 
overall originator prices were 5% higher in markets where 
generic counterparts were available. In Denmark and Swe-
den originator prices were 2.5 and 0.8% lower when generics 
were available, while in Germany, Norway, the UK and the 
Netherlands originator prices were found to be 1.3, 3.8, 4.1 
and 11.3% higher, respectively, for products with generics 
available. Country differences were also analyzed by Clarke 
et al. who showed large differences in wholesale price devel-
opments as well as patterns in generic uptake of simvastatin 
between the UK and Australia [9]. In Australia the price of 
statins decreased by 15% annually after patent expiry, down 
to 50% of the originator price in the first 4 years after patent 
expiry. In the UK the original price was initially higher, but 
the price decreased at more than twice the rate to about 4% 
of the original price over the same period [9]. Additionally 
Kanavos et al. indicated that both originator and generic 
prices varied greatly between countries and products and 
that the minimum generic price is on average 47% lower in 
countries that use reference pricing for generics [19].
4  Discussion
This systematic review disclosed the evidence scarcity 
with regard to the impact of patent expiry on drug prices. 
All included studies suggest that generic entry causes sig-
nificant price competition that leads to an overall decrease 
in pharmaceutical costs, though the extent to which drug 
prices decrease after patent expiry differed between stud-
ies and countries. Different trends were observed in price 
developments after patent expiry between originators and 
generics. Generic drug prices are negatively correlated 
with the number of generic manufacturers in the mar-
ket, although originator prices may increase when more 
generic manufacturers appear to compensate for losses in 
market share.
Availability of drug utilization data is important to 
calculate the overall budget impact, as prices of different 
products can be weighted by their proportionate use. The 
majority of the studies (13 out of 16) included drug-utili-
zation [6, 8–10, 12, 13, 15, 18, 19, 21–24]. By correcting 
overall prices for generic share, strengths, package sizes, 
and administration forms, the calculated weighted aver-
age price represents the price paid by society for a certain 
drug over time. Of the studies included into this review, 
five were able to provide an accurate estimate of the price 
development after patent expiration for the total market 
by correcting for most these factors [6, 12, 13, 15, 18]. 
Drug-utilization should preferably be measured in number 
of DDDs, as this is a global standardized measure that 
enables price-comparison between different strengths and 
administration forms.
In order to make useful predictions on future drug price 
developments or implement data on price developments into 
cost-effectiveness analyses, the data should be complete, up 
to date, and specified towards the specific market within 
the country of interest. Currently available literature shows 
limitations to do so, especially for European countries. Price 
developments over the lifetime of drugs may vary greatly 
between countries as they may apply different pricing and 
reimbursement policies that can influence drug prices over 
time [25]. A well-established methodological framework for 
evaluating drug prices over time that also allows for com-
parison between countries is lacking. Cross-country price 
comparisons are only meaningful if comparable data is used 
to compare the same drug. As such a standardized adminis-
tration form would be required, as well as an identical format 
of price display (such as cost per universal outcome meas-
ures, e.g., price per defined daily dose). For these reasons 
the different studies are hardly comparable in terms of price 
developments over time.
Another limitation is the use of publicly avail-
able prices. These prices do not reflect the confidential 
The Impact of Patent Expiry on Drug Prices
discounts that are often disclosed between manufactur-
ers and governments or decision makers. Although these 
prices do not properly reflect on the total healthcare 
expenditure or possible savings made, these prices are 
the prices that insurers or consumers have to pay. Conse-
quently, these publicly available list prices are the prices 
used within assessments of affordability and cost effective-
ness studies.
Despite the limitations, data on drug price developments 
can be utilized in several ways. The horizon scan is a newly 
introduced method in the Netherlands to track all the innova-
tive drugs that will come to the market as well as drugs that 
will have their patents expire in the near future [26]. Use 
of correct information on price developments after patent 
expiry can help to estimate the impact on the healthcare 
budget of both these new innovative drugs and those that 
will have their patent expired. Besides forecasts on health-
care expenditure price developments during the lifecycle of a 
drug can be used in health economic models to provide more 
realistic estimations on the cost-effectiveness of a new drug.
The majority of the included studies that focused on the 
impact of patent expiry on price used data from before 2000, 
while no study available included data from 2010 onwards. 
Furthermore, the USA is overly represented in the included 
studies with only three studies focusing on a single other 
country. Overall it can be concluded that studies focusing 
on the impact of patent expiry on the total pharmaceutical 
and healthcare costs in the European market are still lack-
ing. None of the included studies investigated the impact 
of patent expiry on price in different therapeutic classes. 
Stratifying outcomes for therapeutic classes could be inter-
esting as one (e.g., cardiovascular drugs) might be more 
appealing for generic competition then others. If different 
therapeutic classes show different trends, then stratification 
should be necessary in order to make more reliable estima-
tions for price developments of future drugs. Next to ther-
apeutic classes biologicals and orphan drugs should also 
be placed into a different segment as different regulations 
apply to these classes of drugs. Moreover, it is important 
that all drugs that faced generic entry over time are included 
to provide a weighted estimated price development that is 
representative for the entire drug market in the country and 
specific field of interest.
5  Conclusion
With limited evidence and knowledge on the impact of pat-
ent expiry on the total pharmaceutical and healthcare costs 
in the European market, a significant decrease in drug prices 
after patent expiry was found. The extent of this price reduc-
tion varied greatly between products and countries. For this 
reason, country-specific analyses on price developments 
after patent expiry should be used when these are considered 
in decision making. Future research should be dedicated to 
gathering more country-specific data to reduce the uncer-
tainty on price developments.
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